Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
Kidney Int
    February 2026
  1. GESUALDO L, Kretzler M, Pontrelli P
    Deep endotyping of renal damage in type 2 diabetes: ex uno, plures.
    Kidney Int. 2026 Feb 27:S0085-2538(26)00143-2. doi: 10.1016/j.kint.2026.
    >> Share

    January 2026
  2. PATEL HA, Wang J, Zinn CJ, Learmonth M, et al
    Targeting Cellular Senescence in Diabetic Kidney Disease: Potential of Regenerative, Cell-based Therapies and Other Senotherapeutic Approaches.
    Kidney Int. 2026 Jan 23:S0085-2538(26)00054-2. doi: 10.1016/j.kint.2025.
    >> Share

  3. SCHUG AP, Ly LT, Eckardt KU, Balzer MS, et al
    The Case | The sweet twirl-chorea as a diabetic complication: an elderly patient with CKD, hyperglycemia, and chorea.
    Kidney Int. 2026;109:235-236.
    >> Share

  4. PRUIJM M, Belmar N, Bjornstad P, Cherney DZI, et al
    REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.
    Kidney Int. 2026;109:6-16.
    >> Share

    November 2025
  5. WANG YH, Chang DY, Zhao YY, Chi-Wai Tang S, et al
    Mitochondrial protein TOMM7 alleviates diabetic kidney disease by regulating mitophagy via intracellular redistribution of phospholipase PLA2G6.
    Kidney Int. 2025 Nov 21:S0085-2538(25)00882-8. doi: 10.1016/j.kint.2025.
    >> Share

  6. NARONGKIATIKHUN P, Bjornstad P
    Unmasking the hidden burden of prediabetes on kidney function.
    Kidney Int. 2025;108:751-753.
    >> Share

  7. MELSOM T, Brobak KM, Norvik JV, Enoksen IT, et al
    Iohexol clearance, but not estimated GFR, reveals a steeper GFR decline in patients with prediabetes.
    Kidney Int. 2025;108:938-947.
    >> Share

    October 2025
  8. LI X, He JC, Lee K
    New potential therapeutic targets of metabolic disorder-associated kidney disease and diabetic kidney disease.
    Kidney Int. 2025 Oct 23:S0085-2538(25)00838-5. doi: 10.1016/j.kint.2025.
    >> Share

  9. NAJAFIAN B, Caramori ML, Vestra MD, Saller A, et al
    Heterogeneity in the relationships between albuminuria and glomerular structure in type 1 and type 2 diabetes.
    Kidney Int. 2025 Oct 6:S0085-2538(25)00771-9. doi: 10.1016/j.kint.2025.
    >> Share

    August 2025
  10. YANG R, Hou Q, Chen R, Ma Z, et al
    Protein UHRF1-mediated dual dysregulation of molecular chaperone GRP78 induces endoplasmic reticulum stress and aggravates diabetic nephropathy.
    Kidney Int. 2025 Aug 25:S0085-2538(25)00654-4. doi: 10.1016/j.kint.2025.
    >> Share

  11. BANSAL A, Chonchol M
    Metabolic dysfunction-associated kidney disease: pathogenesis and clinical manifestations.
    Kidney Int. 2025;108:194-200.
    >> Share

    July 2025
  12. NAVANEETHAN SD, Anker SD, Filippatos G, Pitt B, et al
    Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis.
    Kidney Int. 2025;108:136-144.
    >> Share

  13. IMAMURA M, Kadowaki T, Maeda S
    Genetic studies on metabolic disorder-associated kidney diseases.
    Kidney Int. 2025;108:30-37.
    >> Share

    June 2025
  14. BAVANANDAN S, Noronha IL, Tchokhonelidze I, Liew A, et al
    Metabolic disorder associated kidney disease and diabetic kidney disease in developing countries.
    Kidney Int. 2025 Jun 27:S0085-2538(25)00493-4. doi: 10.1016/j.kint.2025.
    >> Share

  15. ORTIZ A, Arreola Guerra JM, Chan JCN, Jha V, et al
    Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2025 Jun 18:S0085-2538(25)00334-5. doi: 10.1016/j.kint.2025.
    >> Share

  16. VAN LOON E, Gillard P, Naesens M
    SGLT2 inhibitors fulfill their expectations in diabetic kidney transplant recipients.
    Kidney Int. 2025;107:966-969.
    >> Share

    May 2025
  17. DE BOER IH, Caramori ML, Chan JCN, Heerspink HJL, et al
    GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary.
    Kidney Int. 2025;107:767-771.
    >> Share

    April 2025
  18. LI L, Liu Y
    Podocyte aging and diabetic kidney disease.
    Kidney Int. 2025;107:596-598.
    >> Share

    January 2025
  19. LI Y, Duan Y, Chu Q, Lv H, et al
    G-protein coupled receptor GPR124 protects against podocyte senescence and injury in diabetic kidney disease.
    Kidney Int. 2025 Jan 17:S0085-2538(25)00057-2. doi: 10.1016/j.kint.2024.
    >> Share

    December 2024
  20. MIMURA I, Chen Z, Natarajan R
    Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes.
    Kidney Int. 2024 Dec 24:S0085-2538(24)00918-9. doi: 10.1016/j.kint.2024.
    >> Share

  21. FOLESTAD E, Mehlem A, Ning FC, Oosterveld T, et al
    Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.
    Kidney Int. 2024 Dec 15:S0085-2538(24)00872-X. doi: 10.1016/j.kint.2024.
    >> Share

  22. KRISHNAN S, Manoharan J, Wang H, Gupta D, et al
    Corrigendum to "CD248 induces a maladaptive unfolded protein response in diabetic kidney disease." Kidney International 2023;103:304-319.
    Kidney Int. 2024;106:1193-1196.
    >> Share

    November 2024
  23. LV Z, Hu J, Su H, Yu Q, et al
    TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00800-7. doi: 10.1016/j.kint.2024.
    >> Share

  24. MIYAMOTO S, Heerspink HJL, de Zeeuw D, Sakamoto K, et al
    A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
    Kidney Int. 2024;106:972-984.
    >> Share

    September 2024
  25. NARONGKIATIKHUN P, Bjornstad P
    Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes.
    Kidney Int. 2024;106:354-356.
    >> Share

  26. VIVARELLI M, Barratt J, Beck LH Jr, Fakhouri F, et al
    The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2024;106:369-391.
    >> Share

    August 2024
  27. SELVARAJAH V, Robertson D, Hansen L, Jermutus L, et al
    A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
    Kidney Int. 2024 Aug 30:S0085-2538(24)00629-X. doi: 10.1016/j.kint.2024.
    >> Share

    July 2024
  28. HEROLD JM, Wiegrebe S, Nano J, Jung B, et al
    Population-based reference values for kidney function and kidney function decline in 25- to 95-year-old Germans without and with diabetes.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00528-3. doi: 10.1016/j.kint.2024.
    >> Share

  29. DRUEKE TB, Massy ZA
    Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors.
    Kidney Int. 2024;106:12-15.
    >> Share

  30. FENG Y, Sun Z, Fu J, Zhong F, et al
    Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury.
    Kidney Int. 2024;106:50-66.
    >> Share

    June 2024
  31. NANGAKU M
    SGLT2 inhibitor: 2-way superstar in nephrology?
    Kidney Int. 2024;105:1176-1177.
    >> Share

  32. KUME S, Packer M
    SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
    Kidney Int. 2024;105:1172-1176.
    >> Share

  33. YAU K, Cherney DZI, van Raalte DH, Wever BE, et al
    Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
    Kidney Int. 2024;105:1168-1172.
    >> Share

  34. MCEVOY CM, Yuen DA
    Not too much, not too little-just the right amount: the story of YAP in the podocyte.
    Kidney Int. 2024;105:1157-1159.
    >> Share

    May 2024
  35. WADA Y, Kidokoro K, Kondo M, Tokuyama A, et al
    Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging.
    Kidney Int. 2024 May 25:S0085-2538(24)00340-5. doi: 10.1016/j.kint.2024.
    >> Share

  36. HONG YA, Nangaku M
    Endogenous adenine as a key player in diabetic kidney disease progression: an integrated multiomics approach.
    Kidney Int. 2024;105:918-920.
    >> Share

  37. WANG L, Tian H, Wang H, Mao X, et al
    Disrupting circadian control of autophagy induces podocyte injury and proteinuria.
    Kidney Int. 2024;105:1020-1034.
    >> Share

    April 2024
  38. MURPHY DP, Wolfson J, Reule S, Johansen KL, et al
    A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease.
    Kidney Int. 2024 Apr 27:S0085-2538(24)00309-0. doi: 10.1016/j.kint.2024.
    >> Share

    March 2024
  39. NEGRI AL
    Sodium-glucose cotransporter 2 inhibitors in the treatment of refractory hypomagnesemia.
    Kidney Int. 2024;105:638.
    >> Share

  40. SHAH CV
    Sodium-glucose cotransporter 2 inhibition, epidermal growth factor, and magnesium homeostasis: is there a link?
    Kidney Int. 2024;105:638-639.
    >> Share

  41. CHEN JJ, Lee TH, Yang HY
    Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2024;105:442-444.
    >> Share

    February 2024
  42. CHEN J, Wang X, He Q, Yang HC, et al
    Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
    Kidney Int. 2024 Feb 27:S0085-2538(24)00160-1. doi: 10.1016/j.kint.2024.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016